The trial was designed to assess the efficacy and safety of semaglutide, a once-weekly subcutaneous glucagon-like peptide 1 (GLP-1) receptor agonist, in preventing major kidney outcomes, specifically kidney failure, substantial loss of kidney function, and death from kidney or cardiovascular causes, in individuals with type 2 diabetes and chronic kidney disease
Anything else means the solution is compromised
Knowing when and how to adjust your dose, whether that means holding, increasing, decreasing, or stopping, is an essential skill for anyone on a semaglutide protocol
While semaglutide effectively reduces appetite in most individuals, persistent hunger can occur due to insufficient dosing duration, hormonal adaptation, dietary factors, or individual variation in medication response
Eating enough is essential for energy so that they can still work out and let the medication help their body aid them in fat loss (rather than trying to eat as little as possible). Managing common GI side effects The most common side effects of semaglutide are gastrointestinal issues like nausea, vomiting, and diarrhea
